drugset / Trial / NCT05200286
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
A single oral dose study to investigate the PK and safety of olorofim in subjects with severe renal impairment compared to subjects with normal renal function.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2022-12-13
- Completion
- 2022-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olorofim | Small molecule | 120 mg | Oral |